AirInSpace raises $8.5 million (€6 million) in VC financing to expand international market penetration for biodecontamination devices providing elimination of deadly airborne microorganisms

“Our one-of-a-kind technology platform is designed to protect hospital occupants
against airborne biological pathogens and nosocomial infections.
The outstanding inactivation and germicidal effects of our technology
have been proven even against one of the world’s most resistant microorganisms,
Bacillus atrophaeus spores (anthrax surrogate).”
Laurent Fullana, CEO, AirInSpace

ATLANTA and PARIS, Oct. 8, 2007—AirInSpace, the leading supplier of mobile ‘catch and kill’ bioprotection devices in the French medical market, announced today that it has closed on an $8.5 million (€6 million) Series “B” round of financing.

The round was led by Matignon Technologies II FCPR with Oddo AM (through FCPI Générations Futures) as a second investor. Aelios Finance served as financial advisor for the company.